Export 7 results:
Author [ Title(Desc)] Type Year
Filters: Author is Campbell, James D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
R. W. Frenck, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, E. B., Cate, T. R., Edwards, K. M., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., “Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.”, Vaccine, vol. 29, no. 34, pp. 5666-74, 2011.
E
L. A. Jackson, Campbell, J. D., Frey, S. E., Edwards, K. M., Keitel, W. A., Kotloff, K. L., Berry, A. A., Graham, I., Atmar, R. L., C Creech, B., Thomsen, I. P., Patel, S. M., Gutierrez, A. F., Anderson, E. L., Sahly, H. M. El, Hill, H., Noah, D. L., and Bellamy, A. R., “Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.”, JAMA, vol. 314, no. 3, pp. 237-46, 2015.
K. M. Zangwill, Treanor, J. J., Campbell, J. D., Noah, D. L., and Ryea, J., “Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.”, J Infect Dis, vol. 197, no. 4, pp. 580-3, 2008.
S
L. A. Jackson, Frey, S. E., Sahly, H. M. El, Mulligan, M. J., Winokur, P. L., Kotloff, K. L., Campbell, J. D., Atmar, R. L., Graham, I., Anderson, E. J., Anderson, E. L., Patel, S. M., Fields, C., Keitel, W., Rouphael, N., Hill, H., and Goll, J. B., “Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.”, Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
W. A. Keitel, Campbell, J. D., Treanor, J. J., Walter, E. B., Patel, S. M., He, F., Noah, D. L., and Hill, H., “Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.”, J Infect Dis, vol. 198, no. 9, pp. 1309-16, 2008.
J. J. Treanor, Campbell, J. D., Zangwill, K. M., Rowe, T., and Wolff, M., “Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.”, N Engl J Med, vol. 354, no. 13, pp. 1343-51, 2006.
U
M. D. Tapia, Sow, S. O., Lyke, K. E., Haidara, F. Cheick, Diallo, F., Doumbia, M., Traore, A., Coulibaly, F., Kodio, M., Onwuchekwa, U., Sztein, M. B., Wahid, R., Campbell, J. D., Kieny, M. - P., Moorthy, V., Imoukhuede, E. B., Rampling, T., Roman, F., De Ryck, I., Bellamy, A. R., Dally, L., Mbaya, O. Tshiani, Ploquin, A., Zhou, Y., Stanley, D. A., Bailer, R., Koup, R. A., Roederer, M., Ledgerwood, J., Hill, A. V. S., W Ballou, R., Sullivan, N., Graham, B., and Levine, M. M., “Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli”, Lancet Infect Dis, vol. 16, no. 1, pp. 31-42, 2016.